Driehaus Capital Management LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Driehaus Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $60,247 - $72,704	-5,821 Reduced 1.07%	535,717 $6.31 Million
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $5.39 Million - $7.81 Million	-487,030 Reduced 47.35%	541,538 $6.42 Million
Q4 2023 Feb 14, 2024	SELL	$7.58 - $12.25 $45,896 - $74,173	-6,055 Reduced 0.59%	1,028,568 $12.6 Million
Q3 2023 Nov 14, 2023	SELL	$8.95 - $11.35 $11,742 - $14,891	-1,312 Reduced 0.13%	1,034,623 $9.96 Million
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $160,907 - $220,025	20,816 Added 2.05%	1,035,935 $9.32 Million
Q1 2023 May 15, 2023	BUY	$6.3 - $8.39 $23,612 - $31,445	3,748 Added 0.37%	1,015,119 $7.98 Million
Q4 2022 Feb 14, 2023	BUY	$4.2 - $14.24 $2.02 Million - $6.86 Million	481,932 Added 91.03%	1,011,371 $6.84 Million
Q3 2022 Nov 14, 2022	BUY	$9.85 - $16.83 $5.21 Million - $8.91 Million	529,439 New	529,439 $7.68 Million
Q1 2021 May 17, 2021	SELL	$14.69 - $42.57 $734,500 - $2.13 Million	-50,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.88 - $19.47 $644,000 - $973,500	50,000 New	50,000 $950,000

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $250M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.